(Q24244321)

2

0 references

Karla Bergerhoff

3

0 references

Christine Clar

4

0 references

Susanne H Ebrahim

Cochrane Database of Systematic Reviews

5

0 references

publication date

18 October 2006

0 references

published in

0 references

cites work

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone: a review of Japanese clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Meglitinide analogues for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Long-term glycaemic control with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Fatal liver failure associated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Outcome studies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Hyperglycemia and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Analysis and reporting of factorial trials: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Progress with thiazolidinediones in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Dietary advice for the prevention of type 2 diabetes mellitus in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Severe but reversible cholestatic liver injury after pioglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Inhaled insulin in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Performance of an NIDDM screening questionnaire based on symptoms and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Misleading funnel plot for detection of bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Publication bias in meta-analysis: its causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Pioglitazone: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

7 January 2021

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

7 January 2021

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

7 January 2021

Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

1 reference

7 January 2021

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006060.PUB2

7 January 2021